Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(147 produtos)
- Bcr-Abl(103 produtos)
- EGFR(572 produtos)
- FAK(71 produtos)
- FLT(91 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(88 produtos)
- Src(80 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(267 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1483 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK3-IN-1
CAS:JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Fórmula:C26H30ClN7O2Cor e Forma:SolidPeso molecular:508.02JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Fórmula:C17H23N5O4SCor e Forma:SolidPeso molecular:393.46DS21360717
CAS:<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Fórmula:C21H23N7OPureza:98%Cor e Forma:SolidPeso molecular:389.45ALK5-IN-29
CAS:<p>ALK5-IN-29: selective ALK inhibitor, IC50 ≤ 10 nM, curbs tumor growth, aids in cancer research.</p>Fórmula:C24H25FN8Cor e Forma:SolidPeso molecular:444.51EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SCor e Forma:SolidPeso molecular:556.6NVP-AAD777
CAS:<p>NVP-AAD777 is a specific VEGFR-2 inhibitor.</p>Fórmula:C22H14F6N4Pureza:98%Cor e Forma:SolidPeso molecular:448.36JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Fórmula:C19H15FN4OPureza:98.27%Cor e Forma:SolidPeso molecular:334.35EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SCor e Forma:SolidPeso molecular:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:<p>TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.</p>Fórmula:C13H11N3O2Cor e Forma:SolidPeso molecular:241.25VEGFR-2/BRAF-IN-1
<p>VEGFR-2/BRAF-IN-1 inhibits VEGFR-2, BRAF V600E & BRAF WT with IC50 of 49, 63 and 5 nM, triggers apoptosis, and halts G1/S cell cycle.</p>Fórmula:C26H20Cl2F3N5O3S2Cor e Forma:SolidPeso molecular:642.5BLK-IN-2
CAS:<p>BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。</p>Fórmula:C39H41N9O3Cor e Forma:SolidPeso molecular:683.8BCR-ABL-IN-2
CAS:<p>BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).</p>Fórmula:C24H25Cl2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:502.39MAX-40279 hemifumarate
CAS:<p>MAX-40279 hemifumarate inhibits FLT3 and FGFR kinases, showing promise for AML treatment.</p>Fórmula:C48H50F2N12O6S2Cor e Forma:SolidPeso molecular:993.12TG 100801 Hydrochloride
CAS:<p>TG 100801: prodrug for macular degeneration. TG 100572: inhibits kinases (VEGFRs, FGFRs, PDGFRβ, Src family), with varying IC50s.</p>Fórmula:C33H31Cl2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:616.54THS-044
CAS:<p>THS-044 (N-[2-Nitro-4-(Trifluoromethyl)phenyl]morpholin-4-Amine) binding stabilizes the HIF2α PAS-B folded state with a kd of 2 μM and regulates HIF2 activity</p>Fórmula:C11H12F3N3O3Pureza:99.89%Cor e Forma:SolidPeso molecular:291.23Atopaxar Hydrobromide
CAS:<p>Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Fórmula:C29H39BrFN3O5Pureza:98%Cor e Forma:SolidPeso molecular:608.54EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Cor e Forma:SolidPeso molecular:351.4TyK2-IN-2
CAS:TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).Fórmula:C16H18N6OPureza:98%Cor e Forma:SolidPeso molecular:310.35Erbstatin
CAS:<p>Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.</p>Fórmula:C9H9NO3Cor e Forma:SolidPeso molecular:179.17XST-14
CAS:<p>XST-14 is a ULK1 inhibitor.XST-14 induces apoptosis and inhibits the growth of HCC cells.</p>Fórmula:C16H21NO4Pureza:99.84% - 99.84%Cor e Forma:SolidPeso molecular:291.34PD-173956
CAS:<p>PD-173956 is an inhibitor of the Src family tyrosine kinases.</p>Fórmula:C20H13Cl2FN4OCor e Forma:SolidPeso molecular:415.25RET-IN-19
CAS:<p>RET-IN-19, a potent RET inhibitor, anticancer: IC50 6.8 nM (RET-wt), 13.51 nM (RET V804M); for NSCLC research.</p>Fórmula:C28H28N6O4SCor e Forma:SolidPeso molecular:544.62GZD856
CAS:<p>GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.</p>Fórmula:C29H27F3N6OPureza:98%Cor e Forma:SolidPeso molecular:532.56KRN383
CAS:<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Fórmula:C17H17N3O4Cor e Forma:SolidPeso molecular:327.33YLT192
CAS:<p>YLT192 is an orally active and bioavailable VEGFR2 inhibitor. It also has potent antiangiogenic activity and antitumor efficacy.</p>Fórmula:C21H19N3O4Pureza:98%Cor e Forma:SolidPeso molecular:377.39EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Cor e Forma:SolidPeso molecular:526.42JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Fórmula:C19H19ClN2OSCor e Forma:SolidPeso molecular:358.89JG26
CAS:JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively,Fórmula:C19H22Br2N4O6SPureza:98.79% - 99.08%Cor e Forma:SolidPeso molecular:594.27CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Cor e Forma:SolidPeso molecular:303.36DMPQ dihydrochloride
CAS:<p>PDGFRβ inhibitor</p>Fórmula:C16H16Cl2N2O2Pureza:99.51%Cor e Forma:SolidPeso molecular:339.22YH-306
CAS:<p>YH-306 (TRV055 acetate ) is a modulator of the FAK signaling pathway that acts by suppressing colorectal tumor growth and metastasis.</p>Fórmula:C19H18N2O2Pureza:98.06%Cor e Forma:SolidPeso molecular:306.36SJF620
CAS:<p>SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).</p>Fórmula:C41H44N8O7Pureza:98%Cor e Forma:SolidPeso molecular:760.84JAK3/BTK-IN-5
CAS:<p>JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.</p>Fórmula:C19H22ClN7O2Cor e Forma:SolidPeso molecular:415.88Multi-kinase-IN-2
CAS:<p>Orally active Multi-kinase-IN-2 blocks angiokinases including VEGFR, PDGFR, FGFR, and more, reducing AKT/ERK phosphorylation and promoting apoptosis.</p>Fórmula:C34H35N5O3Cor e Forma:SolidPeso molecular:561.67EGA
CAS:EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.Fórmula:C16H16BrN3OPureza:98% - 99.6%Cor e Forma:SolidPeso molecular:346.22ER 27319 maleate
CAS:<p>Selective inhibitor of Syk kinase</p>Fórmula:C22H24N2O5Pureza:98%Cor e Forma:SolidPeso molecular:396.44Momelotinib Mesylate
CAS:<p>Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.</p>Fórmula:C24H26N6O5SPureza:98%Cor e Forma:SolidPeso molecular:510.57JNJ-47117096 hydrochloride
CAS:JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.Fórmula:C21H23ClN4O2Cor e Forma:SolidPeso molecular:398.89TL02-59 dihydrochloride
CAS:<p>TL02-59 dihydrochloride is an orally active inhibitor of Src-family kinase Fgr (IC50: 0.03 nM).</p>Fórmula:C32H36Cl2F3N5O4Pureza:98%Cor e Forma:SolidPeso molecular:682.56Sch 13835
CAS:<p>Sch 13835 is an inhibitor of platelet derived growth factor.</p>Fórmula:C15H10ClNO4SPureza:98%Cor e Forma:SolidPeso molecular:335.76LRRK2/NUAK1/TYK2-IN-1
CAS:<p>LRRK2/NUAK1/TYK2-IN-1 inhibits LRRK2, TYK2, NUAK1 with IC50 < 10 nM, useful in autoimmune research.</p>Fórmula:C20H11F3N6Cor e Forma:SolidPeso molecular:392.34EL-102
CAS:<p>EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer.</p>Fórmula:C19H16N2O3S2Pureza:99.34%Cor e Forma:SolidPeso molecular:384.47PF-06465469
CAS:<p>PF-06465469 is a covalent ITK inhibitor(IC50: 2 nM).</p>Fórmula:C30H33N7O2Pureza:98%Cor e Forma:SolidPeso molecular:523.63EGFR-IN-28
CAS:<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Fórmula:C31H39BrN10O3SCor e Forma:SolidPeso molecular:711.68AP 24149
CAS:<p>AP 24149, a potent dual inhibitor targeting Src and Abl, exhibits IC50 values of 9.1 nM for Src and 3.6 nM for Abl, respectively.</p>Fórmula:C23H24N5OPCor e Forma:SolidPeso molecular:417.44Flonoltinib
CAS:<p>Flonoltinib (JAK2/FLT3-IN-1) is an orally active and efficient JAK2/FLT3 inhibitor with anti-cancer properties.</p>Fórmula:C25H34FN7OPureza:99.52%Cor e Forma:SolidPeso molecular:467.58FGFR-IN-9
<p>FGFR-IN-9: oral FGFR inhibitor, IC50: 17.1 nM (FGFR4 WT), 29.6 (FGFR3), 30.7 (V550L), 46.7 (FGFR2), 64.3 nM (FGFR1).</p>Fórmula:C25H28N6O3SCor e Forma:SolidPeso molecular:492.59Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Fórmula:C27H35ClN6O5SPureza:98%Cor e Forma:SolidPeso molecular:591.12GW837016X
CAS:<p>GW837016X, also known as NEU-391, is a potent inhibitor of protozoan parasite proliferation.</p>Fórmula:C25H20ClFN4OSCor e Forma:SolidPeso molecular:478.97MDK5466
CAS:<p>MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.</p>Fórmula:C21H23N3OSPureza:98%Cor e Forma:SolidPeso molecular:365.49EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OCor e Forma:SolidPeso molecular:354.44HIV-IN-6
CAS:<p>HIV-IN-6, an anti-HIV agent, blocks replication by targeting SFKs like Hck involved with Nef protein.</p>Fórmula:C20H16N4O3SPureza:97.12%Cor e Forma:SolidPeso molecular:392.43TG53
CAS:<p>TG53 is a tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction inhibitor.</p>Fórmula:C21H22ClN5O2Pureza:98%Cor e Forma:SolidPeso molecular:411.88Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Fórmula:C28H28ClN5O4SCor e Forma:SolidPeso molecular:566.07Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Fórmula:C20H25NO5Cor e Forma:SolidPeso molecular:359.42CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Fórmula:C29H25F3N6O3Cor e Forma:SolidPeso molecular:562.54Peficitinib hydrobromide
CAS:<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Fórmula:C18H23BrN4O2Cor e Forma:SolidPeso molecular:407.312EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SCor e Forma:SolidPeso molecular:287.34FM19G11
CAS:<p>FM19G11 is an inhibitor of hypoxia inducible factor (HIF) α-subunit (IC50 = 80 nM in hypoxia induced luciferase assay).</p>Fórmula:C23H17N3O8Pureza:99.70%Cor e Forma:SolidPeso molecular:463.4BTK-IN-9
CAS:<p>BTK-IN-9 reversibly inhibits BTK, disrupts mitochondria, boosts ROS, and triggers apoptosis in Z138 cells, impeding condyloma cell growth.</p>Fórmula:C25H19N7O4Cor e Forma:SolidPeso molecular:481.46FGFR-IN-3
CAS:<p>FGFR-IN-3: potent, oral FGFR modulator, BBB-penetrating, neuroprotective, potential in neurodegeneration study.</p>Fórmula:C18H27F2N5O2Cor e Forma:SolidPeso molecular:383.44TRK II-IN-1
CAS:<p>TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.</p>Fórmula:C29H31F3N8OPureza:98%Cor e Forma:SolidPeso molecular:564.6Derazantinib Racemate
CAS:<p>Derazantinib Racemate is an oral ATP competitive kinase inhibitor targeting FGFR1/2/3 (IC50s: 4.5/1.8/4.5 nM).</p>Fórmula:C29H29FN4OPureza:98%Cor e Forma:SolidPeso molecular:468.57EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Fórmula:C10H6N6S2Cor e Forma:SolidPeso molecular:274.32EGFR-IN-40
CAS:<p>EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).</p>Fórmula:C23H20N6O3Cor e Forma:SolidPeso molecular:428.44(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Fórmula:C17H14N2O3Cor e Forma:SolidPeso molecular:294.3FLT3-IN-11
CAS:<p>FLT3-IN-11, an oral FLT3 kinase inhibitor: potent, selective, IC50 - wild-type 7.22 nM, FLT3-D835Y 4.95 nM, anti-AML IC50 3.2 nM for MV4-11.</p>Fórmula:C20H25F3N6OCor e Forma:SolidPeso molecular:422.45BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Fórmula:C23H27N7OCor e Forma:SolidPeso molecular:417.51RIPK2-IN-1
CAS:<p>RIPK2-IN-1 (compound 18f) is a potent inhibitor of RIPK2 (IC50: 51 nM) and also inhibits ALK2 (IC50: 5 nM).</p>Fórmula:C23H27N5O3SCor e Forma:SolidPeso molecular:453.56J-1048
CAS:<p>J-1048, an activin receptor-like kinase 5 (ALK5) inhibitor, effectively suppresses TAA-induced liver fibrosis in mice through specific inhibition of the TGF-β/</p>Fórmula:C23H17FN6S2Cor e Forma:SolidPeso molecular:460.55FLT3/CDK4-IN-1
CAS:<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Fórmula:C25H28F2N8Cor e Forma:SolidPeso molecular:478.54PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Fórmula:C21H14Cl2N4O3Cor e Forma:SolidPeso molecular:441.27AhR modulator-1
CAS:<p>AhR modulator-1: orally active, selective, inhibits metastasis and prostatic VEGF, anti-estrogenic in rat uterus.</p>Fórmula:C13H7Cl3OPureza:98%Cor e Forma:SolidPeso molecular:285.55BMS-243117
CAS:<p>BMS-243117: Selective LCK inhibitor, IC50=1.1µM, inhibits T cell growth, promising for immunosuppression, arthritis, asthma treatment.</p>Fórmula:C20H21ClN4O2SCor e Forma:SolidPeso molecular:416.92FAK-IN-5
CAS:<p>FAK-IN-5 is a FAK signaling inhibitor that induces apoptosis and autophagy.</p>Fórmula:C29H29ClF3N3O4Cor e Forma:SolidPeso molecular:576.01Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Fórmula:C23H22F5N7OCor e Forma:SolidPeso molecular:507.469JS25
CAS:<p>JS25, a selective BTK inhibitor, inactivates it with a 5.8 nM IC50, halts cancer cell growth, induces death, and aids against lymphoma.</p>Fórmula:C29H24N4O4SCor e Forma:SolidPeso molecular:524.59(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Fórmula:C15H19N5OCor e Forma:SolidPeso molecular:285.34MBM-55S
CAS:<p>MBM-55S, a Nek2 inhibitor with 1 nM IC50, induces cell cycle arrest and apoptosis, suppressing tumor growth.</p>Fórmula:C36H39FN6O10Pureza:99.37% - 99.89%Cor e Forma:SolidPeso molecular:734.73ALK-IN-22
CAS:<p>ALK-IN-22 suppresses ALK and mutants (IC50: 2.3-3.7 nM), hinders phosphorylation, and induces apoptosis in tumor studies.</p>Fórmula:C24H24ClN7O2Cor e Forma:SolidPeso molecular:477.95QL-X-138
CAS:<p>QL-X-138: Dual BTK/MNK inhibitor; covalent to BTK, IC50=9.4 nM; non-covalent to MNK1/2, IC50=107.4/26 nM; dengue virus 2 IC50=3.5 μM; for B-cell malignancies.</p>Fórmula:C25H19N5O2Pureza:98.82% - 99.50%Cor e Forma:SolidPeso molecular:421.45BTK inhibitor 10
CAS:BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.Fórmula:C25H23N5O3Pureza:98%Cor e Forma:SolidPeso molecular:441.484-DAMP
CAS:<p>4-DAMP (4-DAMP methiodide) is a selective muscarinic M1 and M3 subtype receptor antagonist used in the study of allergic rhinitis and cardiovascular disease.</p>Fórmula:C21H26INO2Pureza:98%Cor e Forma:SolidPeso molecular:451.34HS-438
CAS:<p>HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.</p>Fórmula:C17H17N3O3SCor e Forma:SolidPeso molecular:343.4EGFR-IN-88
CAS:<p>EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosis</p>Fórmula:C22H18Cl2N4O2SPureza:98%Cor e Forma:SolidPeso molecular:473.37BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Fórmula:C24H27FN4O4Cor e Forma:SolidPeso molecular:454.49TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Fórmula:C22H25F2N5O2Cor e Forma:SolidPeso molecular:429.46Cyt-PTPε Inhibitor-1
CAS:Cyt-PTPε Inhibitor-1 (A Inhibitor-1) is an inhibitor of cytosolic protein tyrosine phosphatase ε.Fórmula:C19H20N4O2SPureza:99.55% - 99.82%Cor e Forma:SolidPeso molecular:368.45PP2 Analog
CAS:PP2 Analog is an analog of PP2. It also acts as a protein trafficking modulator.Fórmula:C16H17ClN4Pureza:98%Cor e Forma:SolidPeso molecular:300.79Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Cor e Forma:SolidPeso molecular:362.86HP1328
CAS:<p>HP1328: potent FLT3/ITD inhibitor, reduces leukemia, extends survival in mice, belongs to benzoimidazole family.</p>Fórmula:C23H23N3O3Cor e Forma:SolidPeso molecular:389.45FGFR4-IN-5
CAS:<p>FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.</p>Fórmula:C23H23Cl2N5O5Cor e Forma:SolidPeso molecular:520.37FLT3-IN-17
CAS:<p>FLT3-IN-17: FAK inhibitor, IC50 of 12 nM; blocks CYPs, FLT3 mutants; IC50 <0.5 nM for D835Y in cancer studies.</p>Fórmula:C23H24N6O2S2Cor e Forma:SolidPeso molecular:480.61ACP-5862
CAS:ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.Fórmula:C26H23N7O3Cor e Forma:SolidPeso molecular:481.51DPPY
CAS:<p>DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.</p>Fórmula:C25H26ClN7O3Cor e Forma:SolidPeso molecular:507.97c-Met-IN-11
CAS:<p>c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).</p>Fórmula:C30H20F2N4O3Cor e Forma:SolidPeso molecular:522.5LS-104
CAS:<p>LS-104 is a JAK2 inhibitor.</p>Fórmula:C19H16N2O3Cor e Forma:SolidPeso molecular:320.34NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Cor e Forma:SolidPeso molecular:348.39TGFBR1-IN-1
CAS:TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM).Fórmula:C23H17N5O2SPureza:98%Cor e Forma:SolidPeso molecular:427.48BLK degrader 1
CAS:<p>BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.</p>Fórmula:C32H25F3N6O2Pureza:99.22% - 99.24%Cor e Forma:SolidPeso molecular:582.58
